The Safety and Efficacy of Standard-Dose versus Low-Dose Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation and Left Atrial Appendage Thrombus
Table 1
Baseline characteristics.
Standard-dose group
Low-dose group
value
n
14
10
—
Age, years
64.4 ± 5.9
68.9 ± 9.6
0.171
Male, n (%)
7 (50)
5 (50)
1.000
Persistent AF, n (%)
5 (35.7)
4 (40)
1.000
Hypertension, n (%)
8 (57.1)
8 (80)
0.388
Diabetes mellitus, n (%)
3 (21.4)
2 (20)
1.000
Congestive heart failure, n (%)
2 (14.3)
2 (20)
1.000
Previous TIA/stroke, n (%)
4 (28.6)
4 (40)
0.673
Previous bleeding, n (%)
3 (21.4)
2 (20)
1.000
CHA2DS2-VASc score, points
3 (2.5, 4)
4 (3, 6)
0.049
HAS-BLED score, points
1.5 (1, 2)
2.5 (2, 4)
0.069
CrCl, mL/min
96.4 ± 10.1
68.5 ± 9.6
<0.001
LA diameter, mm
44.2 ± 8.6
45.3 ± 5.8
0.731
LVEF, %
57.0 ± 12.8
58.6 ± 12.1
0.760
LAA orifice diameter, mm
21.0 ± 3.0
21.8 ± 2.8
0.521
AF: atrial fibrillation; TIA: transient ischemic attack; CrCl: creatinine clearance; LA: left atrium; LVEF: left ventricular ejection fraction; LAA: left atrial appendage.
